---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-030701"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:54:28.675671+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech reports Q2 net loss $9.4M, clinical updates on PDS0101 and PDS01ADC

## Summary
- Net loss $9.4M ($0.21/dil share) vs $8.3M ($0.23) in Q2 2024.
- R&D $4.2M, G&A $3.4M; total operating expenses $7.6M vs $8.7M.
- Cash $31.9M (6/30/25) vs $41.7M (12/31/24); net interest expense $1.8M vs $0.5M.
- Colorectal cancer cohort of Phase 2 trial with PDS01ADC met expansion criteria (≥6 of 9 objective responses).
- Phase 3 VERSATILE-003 trial for PDS0101 in HPV16+ HNSCC progressing; 3 ASCO 2025 abstracts presented.

## SEC filing metadata
- accession: 0001140361-25-030701
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036125030701/0001140361-25-030701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036125030701/ef20053853_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-030701
- JSON: https://secwatch.observer/filing/0001140361-25-030701.json
- Plain text: https://secwatch.observer/filing/0001140361-25-030701.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.